Pam Bondi, Donald Trump’s pick for Attorney General, has been revealed to have represented Pfizer while working at Panza, Maurer & Maynard, raising serious concerns about conflicts of interest as she steps into DOJ leadership.
Why it matters: Bondi’s profitable connections with major pharmaceutical companies and foreign organizations risk compromising American justice, favoring corporate gains over the well-being and confidence of U.S. citizens who merit an untainted judicial system.
Driving the news: A recent financial disclosure reveals Bondi received $203,738 in 2024 from Panza, Maurer & Maynard, where she managed litigation for Pfizer, in addition to $1.1 million from lobbying powerhouse Ballard Partners, as reported by Law.com.
- Her work for Pfizer included corporate and regulatory issues, spotlighting potential bias toward pharmaceutical giants.
- Bondi’s $12 million net worth, boosted by $3 million from Trump Media’s merger, underscores her deep entanglements with elite interests.
- Democrats at her confirmation hearing flagged her lobbying for Uber, Amazon, and Qatar as conflicts, amplifying scrutiny.
Catch up quick: Bondi, a former Florida Attorney General, joined Ballard Partners and Panza, Maurer & Maynard after leaving office, bringing in millions while leading the America First Policy Institute. Her promise to resign, if verified, seeks to resolve ethical concerns, yet her previous work for Pfizer remains a significant concern.
The intrigue: Bondi’s dual role serving corporate clients like Pfizer while aligning with Trump’s agenda suggests a pattern of favoring powerful lobbies over everyday Americans.
Between the lines: Her financial windfall from Trump Media and lobbying gigs reveals a swamp creature thriving in D.C., where justice could be swayed by the highest bidder rather than the public good.
What they’re saying:
- “Bondi earned $203,738 for legal services… her clients included Pfizer Inc.,” Law.com disclosed, highlighting her Big Pharma ties.
- “Her lobbying work… was a point of contention,” the report noted, reflecting bipartisan unease over her impartiality.
The bottom line: Bondi’s Pfizer connection demands a thorough vetting—Americans deserve an AG free from corporate influence, not one beholden to the very entities she’d oversee.
